Longboard Pharmaceuticals Receives Rare Pediatric Disease And Orphan Drug Designations From FDA For Bexicaserin (LP352) In Dravet Syndrome
Portfolio Pulse from Benzinga Newsdesk
Longboard Pharmaceuticals has received Rare Pediatric Disease and Orphan Drug Designations from the FDA for its drug Bexicaserin (LP352) aimed at treating Dravet Syndrome. These designations can provide benefits such as market exclusivity and financial incentives.
September 19, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longboard Pharmaceuticals received FDA designations for Bexicaserin (LP352) in Dravet Syndrome, potentially leading to market exclusivity and financial incentives.
The FDA designations are significant as they can lead to market exclusivity and financial incentives, which are positive for Longboard Pharmaceuticals' future revenue potential. This news is likely to positively impact LBPH's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100